Use of cryoprotectant-depleted allogeneic peripheral blood stem cells for transplantation
Authors: Hirata, Yuji1; Kishino, Koji1; Onozaki, Fumiko1; Nakaki, Yoko1; Fujiwara, Shin-ichiro2; Yamamoto, Chizuru1; Sato, Kazuya2; Matsuyama, Tomohiro1; Ozaki, Katsutoshi2; Mori, Masaki1; Ozawa, Keiya1; Muroi, Kazuo1
Source: Hematology, Volume 16, Number 4, July 2011 , pp. 221-224(4)
Publisher: Maney Publishing
Transplantation with cryopreserved allogeneic peripheral blood stem cells (PBSCs) from related donors is widely conducted in Japan. To freeze PBSCs, a solution containing dimethyl sulfoxide (DMSO), which can have various adverse effects, is added. DMSO-depleted allogeneic PBSCs were transplanted into 21 patients. The cryoprotectant was manually removed from thawed PBSCs and the cells were mixed with a solution containing citrate dextrose as an anticoagulant and RPMI-1640 medium. DMSO-depleted PBSCs were immediately infused into patients subjected to conditioning. Infusion-related adverse effects were only observed in three patients. The median neutrophil recovery (0·5×109/l) and platelet recovery (20×109/l) were 13·0 and 14·0 days, respectively. Only one patient with mixed-lineage leukemia in non-complete remission did not show engraftment, likely due to a second transplantation and a two-antigen disparity in human leukocyte antigen system A. The results suggest the removal of DMSO from thawed PBSCs to be safe and useful for transplantation.
Document Type: Original Article
Publication date: 2011-07-01